# DESCRIPTION

## FIELD OF THE INVENTION

- relate to novel binding interactions

## BACKGROUND OF THE INVENTION

- introduce S100A9 protein
- describe S100A9 functions
- describe RAGE receptor
- describe TLR receptors

## SUMMARY OF THE INVENTION

- characterize novel binding interactions
- describe method of identifying compounds

## DESCRIPTION OF THE SEQUENCES MENTIONED HEREIN

- list sequence IDs

## DETAILED DESCRIPTION OF THE INVENTION

- introduce method for identifying therapeutic compounds
- specify compounds for use in cancer therapy or immunotherapy
- describe conditions that can be prevented or treated by modulation of the immune system
- specify individual to be treated in the therapy
- describe binding assays carried out under specific conditions
- identify therapeutic compounds based on their ability to modulate interaction between S100A9 and a ligand
- specify ligands, such as RAGE or TLR
- describe suitable assays for measuring physical properties
- describe determining whether a candidate compound affects the binding of S100A9 and a ligand
- describe allowing the candidate compound to bind S100A9 and then determining whether the binding would affect the binding of S100A9 to RAGE or
- define "modulate" as used in the invention
- describe using S100A9 and/or the ligand and/or the compound in isolated form or substantially isolated form
- specify conditions for the method, such as presence of calcium and zinc ions
- describe immobilizing S100A9 or the ligand to a solid surface
- describe measuring the binding of S100A9 and ligand over a certain time period
- describe measuring the effects of different amounts/concentrations of the compound
- list characteristics for measuring and/or selecting a compound
- describe testing at least 100 candidate compounds
- list characteristics of the candidate compounds
- describe using a suitable structural element in the candidate compounds
- describe selecting less than 5% of the compounds which are tested

### Homologues

- define homologues of sequences
- specify homology percentages
- describe calculating homology using BESTFIT program
- describe using PILEUP and BLAST algorithms to calculate homology
- describe performing BLAST analyses
- describe the BLAST algorithm parameters
- describe the smallest sum probability (P(N))

### Further Testing of the Identified Compound

- describe further testing of the identified compound
- describe cell-based assays or animal model assays
- describe testing the compound in an animal model
- describe administering the compound to an animal and determining its effect

### The Antibody of the Invention

- describe antibody 43/8
- introduce epitope on S100A9
- define antibody specificity
- describe antibody binding to S100A9
- introduce Ca2+ and Zn2+ dependence
- describe antibody stimulation of TNFα production
- describe antibody induction of NFκB reporter gene
- define antibody epitope recognition
- introduce antibody obtainability by immunization
- describe antibody therapeutic usefulness
- introduce antibody purification and isolation
- define antibody specificity for epitope
- describe antibody production methods
- introduce antibody fragments
- describe antibody species and types
- define antibody purification and isolation

### Administration

- introduce pharmaceutical composition
- describe disease treatment options
- introduce formulation factors
- describe oral administration
- describe parenteral administration
- introduce pharmaceutical carrier or diluent
- describe liquid dispersions
- introduce therapeutically effective dose

### Proteomic Screen

- describe proteomic screen results

### The Biacore Assay

- introduce Biacore assay system

### The Immobilization of RAGE to a Chip

- describe RAGE immobilization
- introduce recombinant human RAGE receptor
- describe biological activity of immobilized RAGE

### The Novel Interaction S100A9 and RAGE

- demonstrate binding of S100A9 to RAGE
- show sigmoidal dose-response curve
- determine optimal zinc ion concentration
- compare binding of S100A9 to RAGE with other RAGE binders
- implicate binding site on S100A9
- show weak or no binding with putative RAGE ligands
- suggest interaction with glycans on RAGE
- demonstrate displacement of S100A9 binding to RAGE by heparin or heparan sulfate
- modulate binding of S100A9 to RAGE with compound A
- immobilize TLR4 on chip
- detect binding of S100A9 to TLR4
- calculate apparent dissociation constant and on- and off-rates
- displace S100A9 binding to TLR4 with compound A
- show surface expression of S100A9 on human monocytes
- design in vitro assay for S100A9 binding compounds
- show effect of S100A9 binding compounds on dendritic cell populations

## Materials and Methods

### Compound A

- synthesize compound A

### Biosensor Analysis

- describe SPR technology
- outline biosensor analysis cycle

### Immobilization of RAGE

- obtain recombinant human RAGE
- change buffer to HBS-P
- covalently couple RAGE to sensor chip
- test activity of immobilized RAGE

### Immobilization of TLR4/MD-2 Complex

- obtain recombinant human TLR4/MD-2
- change buffer to HBS-P
- covalently couple TLR4/MD-2 to sensor chip

### Competition Assay

- describe competition assay format

### Evaluation of Binding Data

- evaluate binding data using BIAevaluation Software

### Purification of Splenic DCs and Human PBMCs

- purify splenic DCs and human PBMCs

### MLR Reactions

- describe MLR reaction protocol

### Analysis of Cell Subsets by Flow Cytometry

- analyze cell subsets by flow cytometry

## Autoimmune Disease Models

- describe autoimmune disease models
- outline experimental lupus model in MRL lpr/lpr mice
- outline nonobese diabetic (NOD) mouse model for autoimmune IDDM

### The Nonobese Diabetic (NOD) Mouse Model for Autoimmune Insulin-Dependent Diabetes Mellitus (IDDM)

- describe NOD mouse model
- outline treatment with compound A
- evaluate development of overt diabetes

## Generation of Anti-S100A9 Monoclonal Antibody 43/8

- immunize mouse with S100A9 protein

### BIACORE™ Assays Demonstrates the Binding Ability of the Anti-S100A9 mAb 43/8

- demonstrate binding of S100A8, S100A9, and S100A8/S100A9 complex to anti-S100A9 m
- show dependence on metal ions Zn2+ and Ca2+

### The Anti-S100A9 mAb 43/8 is Specific to Human S100A9

- demonstrate specificity for human S100A9 by BIACORE assay
- show reactivity towards human S100A8/S100A9 complex and human S100A12
- show weak or no reactivity for other human and murine S100 proteins
- describe preparation of S100 proteins for analysis

### The Anti-S100A9 mAb 43/8 Blocks Binding of Human S100A9 to TLR4/MD-2

- describe blocking of S100A9 binding to TLR4/MD-2 by anti-S100A9 mAb 43/8
- perform BIACORE assay to measure blocking
- calculate IC50 value for blocking
- describe transformation of binding data

### The Anti-S100A9 Antibody Recognizes a Unique Epitope

- demonstrate recognition of unique epitope by anti-S100A9 mAb 43/8
- compare blocking of S100A9 binding by anti-S100A9 mAb 43/8 and 1C10
- describe preparation of samples for BIACORE assay

### The Anti-S100A9 mAb 43/8 Stimulates TNFα-Production in Peripheral Blood Mononuclear Cells

- stimulate TNFα production in human peripheral blood monocytes

### The Anti-S100A9 mAb 43/8 Stimulates an NFκB Reporter Gene in LNCaP Cells

- stimulate NFκB reporter gene activity in LNCaP cells

## Conclusion

- summarize properties of anti-S100A9 monoclonal antibody

### Compound A is an Efficient Modulator of S100A9 Binding to RAGE and TLR4

- compare Compound A to Rolipram in modulating S100A9 binding
- describe calculation of IC50 values for Compound A and Rolipram

